CD8A and melanoma: induces the proliferation of CD4+ or CD8+ T cells, increases the production and differentiation of Treg cells, and upregulates the expression of inducible T cell costimulatory, thereby decreasing the risk of ICI-related colitis and improving the response to ICIs in melanoma patients [57].